secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001193125-23-129712
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon provides pipeline and AP3 update, reports cash runway into Q4 2024
--------------------------------------------------------------------------

- Hosted virtual investor event on May 1, 2023 with updated corporate presentation.
- Disclosed cash and marketable securities as of March 31, 2023 (amount not specified in filing).
- Confirmed cash runway extends into at least Q4 2024.
- Presentation highlights progress on AP3 precision proteomics platform and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523129712/0001193125-23-129712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523129712/d283996d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-129712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer